NOK 10.7 million supports circular mRNA technology
Biotechnology company Circio Holding has secured approximately NOK 10.7 million (€907.4k) in financing to support the development of its circVec circular mRNA technology.
The major allocations in the financing were to existing shareholders Høse AS and Bækkelaget Holding AS, and new shareholders Star Kapital AS (v/ Tom A Thorsen) and an undisclosed Norwegian investor.
The proceeds will be dedicated to accelerating development of Circio’s circVec circular RNA technology to establish in vivo proof-of-concept for its lead gene therapy programme, and to expand the platform into a new cell therapy approach.
“Following the recently published circVec 3.0 generation data, Circio has experienced very strong warrant exercise demand, both from existing and new shareholders. In order to satisfy some of the additional interest and allow allocation to two new experienced biotech investors, the offering was upsized with a parallel private placement,” said Dr Erik Wiklund, CEO at Circio.
“The additional funding will allow Circio to further accelerate the development of the circVec platform, with the aim of securing our first partnership during 2025. In addition, we now have a strengthened cap-table to support the company long-term, and a reduced need to draw future tranches from Atlas.”
Circio’s circVec technology is based on a modular genetic cassette design for biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed in multiple disease settings, including cell and gene therapy and chronic diseases.
Circio is also developing a pan-RAS cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in two clinical trials: RAS-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative networks, supported by research grants from Innovation Norway and the Norwegian Research Council.
Diana Spencer, Senior Digital Content Editor, DDW
